Renin-Angiotensin System Modulation with Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults with COVID-19: Two Randomized Clinical Trials

Wesley H. Self, Matthew S. Shotwell, Kevin W. Gibbs, Marjolein De Wit, D. Clark Files, Michelle Harkins, Kristin M. Hudock, Lisa H. Merck, Ari Moskowitz, Krystle D. Apodaca, Aaron Barksdale, Basmah Safdar, Ali Javaheri, Jeffrey M. Sturek, Harry Schrager, Nicole Iovine, Brian Tiffany, Ivor S. Douglas, Joseph Levitt, Laurence W. BusseAdit A. Ginde, Samuel M. Brown, David N. Hager, Katherine Boyle, Abhijit Duggal, Akram Khan, Michael Lanspa, Peter Chen, Michael Puskarich, Derek Vonderhaar, Lokesh Venkateshaiah, Nina Gentile, Yves Rosenberg, James Troendle, Amanda J. Bistran-Hall, Josh Declercq, Robert Lavieri, Meghan Morrison Joly, Michael Orr, Jill Pulley, Todd W. Rice, Jonathan S. Schildcrout, Matthew W. Semler, Li Wang, Gordon R. Bernard, Sean P. Collins

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Importance: Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an important contributor to COVID-19 pathophysiology. Objective: To evaluate the efficacy and safety of RAS modulation using 2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand), that are hypothesized to potentiate the action of angiotensin (1-7) and mitigate the action of the angiotensin II. Design, Setting, and Participants: Two randomized clinical trials including adults hospitalized with acute COVID-19 and new-onset hypoxemia were conducted at 35 sites in the US between July 22, 2021, and April 20, 2022; last follow-up visit: July 26, 2022. Interventions: A 0.5-mg/kg intravenous infusion of TXA-127 once daily for 5 days or placebo. A 12-mg/h continuous intravenous infusion of TRV-027 for 5 days or placebo. Main Outcomes and Measures: The primary outcome was oxygen-free days, an ordinal outcome that classifies a patient's status at day 28 based on mortality and duration of supplemental oxygen use; an adjusted odds ratio (OR) greater than 1.0 indicated superiority of the RAS agent vs placebo. A key secondary outcome was 28-day all-cause mortality. Safety outcomes included allergic reaction, new kidney replacement therapy, and hypotension. Results: Both trials met prespecified early stopping criteria for a low probability of efficacy. Of 343 patients in the TXA-127 trial (226 [65.9%] aged 31-64 years, 200 [58.3%] men, 225 [65.6%] White, and 274 [79.9%] not Hispanic), 170 received TXA-127 and 173 received placebo. Of 290 patients in the TRV-027 trial (199 [68.6%] aged 31-64 years, 168 [57.9%] men, 195 [67.2%] White, and 225 [77.6%] not Hispanic), 145 received TRV-027 and 145 received placebo. Compared with placebo, both TXA-127 (unadjusted mean difference, -2.3 [95% CrI, -4.8 to 0.2]; adjusted OR, 0.88 [95% CrI, 0.59 to 1.30]) and TRV-027 (unadjusted mean difference, -2.4 [95% CrI, -5.1 to 0.3]; adjusted OR, 0.74 [95% CrI, 0.48 to 1.13]) resulted in no difference in oxygen-free days. In the TXA-127 trial, 28-day all-cause mortality occurred in 22 of 163 patients (13.5%) in the TXA-127 group vs 22 of 166 patients (13.3%) in the placebo group (adjusted OR, 0.83 [95% CrI, 0.41 to 1.66]). In the TRV-027 trial, 28-day all-cause mortality occurred in 29 of 141 patients (20.6%) in the TRV-027 group vs 18 of 140 patients (12.9%) in the placebo group (adjusted OR, 1.52 [95% CrI, 0.75 to 3.08]). The frequency of the safety outcomes was similar with either TXA-127 or TRV-027 vs placebo. Conclusions and Relevance: In adults with severe COVID-19, RAS modulation (TXA-127 or TRV-027) did not improve oxygen-free days vs placebo. These results do not support the hypotheses that pharmacological interventions that selectively block the angiotensin II type 1 receptor or increase angiotensin (1-7) improve outcomes for patients with severe COVID-19. Trial Registration: Identifier: NCT04924660.

Original languageEnglish
Pages (from-to)1170-1182
Number of pages13
Issue number14
StatePublished - Apr 11 2023


Dive into the research topics of 'Renin-Angiotensin System Modulation with Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults with COVID-19: Two Randomized Clinical Trials'. Together they form a unique fingerprint.

Cite this